Avalo Therapeutics (AVTX) director awarded 40,200 stock options at $17.83 strike
Rhea-AI Filing Summary
Avalo Therapeutics director Philip Ron received a grant of stock options covering 40,200 shares of common stock at an exercise price of $17.83 per share. The options vest in three substantially equal annual installments on the first, second and third anniversaries of the June 23, 2026 grant date, contingent on continued board service. Following this award, his reported option holdings from this filing total 40,200 derivative securities.
Positive
- None.
Negative
- None.
Insights
Routine director stock option grant with multi-year vesting, neutral signal.
The filing shows Avalo Therapeutics granted director Philip Ron stock options for 40,200 shares at an exercise price of $17.83, expiring on June 23, 2036. This is classified as a grant or award, not an open-market purchase.
The options vest in three substantially equal annual installments over three years, conditioned on continued director service. This structure encourages longer-term alignment with shareholders but is typical for board compensation. No sales or exercises are reported, so the overall signal remains neutral.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Philip Ron M
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 40,200 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 40,200 shares (Direct)
Footnotes (1)
- F1. The stock option vests in three substantially equal annual installments on the first, second and third anniversary of the date of grant, subject to the Eligible Director's continued service on each such vesting date.
Key Figures
Option grant size: 40,200 options
Exercise price: $17.83 per share
Shares underlying options: 40,200 shares
+3 more
6 metrics
Option grant size
40,200 options
Stock Option (Right to Buy) granted June 23, 2026
Exercise price
$17.83 per share
Exercise price for 40,200 option shares
Shares underlying options
40,200 shares
Common Stock underlying granted options
Post-grant derivative holdings
40,200 derivative securities
Total options held following transaction
Option expiration
June 23, 2036
Expiration date of granted options
Vesting schedule
3 annual installments
Vests over three substantially equal annual installments
Key Terms
Stock Option (Right to Buy), exercise price, vesting, expiration date, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 17.8300"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The stock option vests in three substantially equal annual installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"expiration_date: 2036-06-23T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
FAQ
What did Avalo Therapeutics (AVTX) director Philip Ron receive in this Form 4?
Philip Ron received a stock option grant for 40,200 shares of Avalo Therapeutics common stock. The options are a compensation award, not an open-market share purchase, and give him the right to buy shares at a fixed exercise price in the future.
What is the exercise price of the Avalo Therapeutics (AVTX) options granted to Philip Ron?
The stock options granted to Philip Ron have an exercise price of $17.83 per share. This means he can buy Avalo Therapeutics common stock at $17.83 if he exercises the options after they vest and before they expire in 2036.
How do the Avalo Therapeutics (AVTX) options to Philip Ron vest?
The options vest in three substantially equal annual installments on the first, second, and third anniversaries of the grant date. Vesting is conditioned on Ron’s continued service as an eligible director on each vesting date, aligning compensation with ongoing board participation.
When do Philip Ron’s Avalo Therapeutics (AVTX) stock options expire?
The stock options granted to Philip Ron expire on June 23, 2036. He must exercise vested options before this expiration date to acquire Avalo Therapeutics common shares at the fixed $17.83 exercise price, subject to the plan’s and award’s specific terms.
Does this Avalo Therapeutics (AVTX) Form 4 show any stock sales by Philip Ron?
No stock sales are reported in this Form 4. It only shows a grant of 40,200 stock options as a compensation award, with no open-market buying or selling activity disclosed for Avalo Therapeutics shares in the reported transaction data.
AI-generated analysis. How Rhea-AI works. Not financial advice.
